No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38

Ophthalmology

Volumn 121, Issue 11, 2014, Pages 2173-2180

  Chew, Emily Y ^a   Klein, Michael L ^b   Clemons, Traci E ^c   Agrón, Elvira ^a   Ratnapriya, Rinki ^d   Edwards, Albert O ^b,e,g   Fritsche, Lars G ^f   Swaroop, Anand ^d   Abecasis, Gonçalo R ^f  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c EMMES CORPORATION   (United States)

^d NATIONAL EYE INSTITUTE   (United States)

^e LLP   (United States)

^f UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF OREGON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; COMPLEMENT FACTOR H; CUPRIC OXIDE; PLACEBO; ZINC OXIDE; ANTIOXIDANT; ARMS2 PROTEIN, HUMAN; COMPLEMENT FACTOR H, HUMAN; PROTEIN; VITAMIN; ZINC DERIVATIVE;

AGE RELATED EYE DISEASE; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; ETHNICITY; EVALUATION STUDY; EYE DISEASE; FEMALE; FOLLOW UP; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL SUPPLEMENTATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIET SUPPLEMENTATION; GENETICS; MACULAR DEGENERATION; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIOXIDANTS; COMPLEMENT FACTOR H; DIETARY SUPPLEMENTS; FEMALE; GENOTYPE; HUMANS; MACULAR DEGENERATION; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROTEINS; RETROSPECTIVE STUDIES; VITAMINS; ZINC COMPOUNDS;

EID: 84908470159     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.05.008     Document Type: Article

References (25)

1. Eye Diseases Prevalence Research Group Causes and prevalence of visual impairment among adults in the United States Arch Ophthalmol 122 2004 477 485
2. Age-Related Eye Disease Study Research Group A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 Arch Ophthalmol 119 2001 1417 1436
3. C. Delcourt, J.L. Diaz, A. Ponton-Sanchez, L. Papoz POLA Study Group Smoking and age-related macular degeneration. The POLA Study Arch Ophthalmol 116 1998 1031 1035
4. Age-Related Eye Disease Study Research Group Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS): AREDS report no. 19 Ophthalmology 112 2005 533 539
5. J.P. SanGiovanni, E.Y. Chew, E. Agron Age-Related Eye Disease Study Research Group The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23 Arch Ophthalmol 126 2008 1274 1279
6. Age-Related Eye Disease Study Research Group The relationship of dietary carotenoid and vitamin A, E, and C with age-related macular degeneration in a case-control study: AREDS report no. 22 Arch Ophthalmol 125 2007 1225 1232
7. J.M. Seddon, J. Cote, N. Davis, and B. Rosner Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio Arch Ophthalmol 121 2003 785 792
8. R. van Leeuwen, M.K. Ikram, and J.R. Vingerling Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study Invest Ophthalmol Vis Sci 44 2003 3771 3777
9. A. Cougnard-Grégoire, M.N. Delyfer, and J.F. Korobelnik Long-term blood pressure and age-related macular degeneration: the ALIENOR study Invest Ophthalmol Vis Sci 54 2013 1905 1912
10. AMD Gene Consortium Seven new loci associated with age-related macular degeneration Nat Genet 45 2013 433 439
11. K. Westbrook, and V. Stearns Pharmacogenomics of breast cancer therapy: an update Pharmacol Ther 139 2013 1 11
12. A. Emadi, and J.E. Karp The clinically relevant pharmacogenomic changes in acute myelogenous leukemia Pharmacogenomics 13 2012 1257 1269
13. M.A. Brantley Jr., A.M. Fang, and J.M. King Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab Ophthalmology 114 2007 2168 2173
14. A.Y. Lee, A.K. Raya, and S.M. Kymes Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab Br J Ophthalmol 93 2009 610 613
15. P.J. Francis The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis) Trans Am Ophthalmol Soc 109 2011 115 156
16. C. Nischler, H. Oberkofler, and C. Ortner Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration [report online] Acta Ophthalmol 89 2011 e344 e349
17. A. Orlin, D. Hadley, and W. Chang Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration Retina 32 2012 4 9
18. S.A. Hagstrom, G.S. Ying, G.J. Pauer Comparison of AMD Treatments Trials Research Group Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatments Ophthalmology 120 2013 593 599
19. R.P. Finger, S.S. Wickremasinghe, P.N. Baird, and R.H. Guymer Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration Surv Ophthalmol 59 2014 1 18
20. M.L. Klein, P.J. Francis, and B. Rosner CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration Ophthalmology 115 2008 1019 1025
21. C.C. Awh, A.M. Lane, and S. Hawken CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration Ophthalmology 120 2013 2317 2323
22. Age-Related Eye Disease Study Research Group The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1 Control Clin Trials 20 1999 573 600
23. W. Chen, D. Stambolian, A.O. Edwards Complications of Age-Related Macular Degeneration Prevention Trial (CAPT) Research Group Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration Proc Natl Acad Sci U S A 107 2010 7401 7406
24. 1000 Genomes Project Consortium An integrated map of genetic variation from 1,092 human genomes Nature 491 2012 56 65
25. L.G. Fritsche, R.N. Fariss, and D. Stambolian Age-related macular degeneration: genetics and biology coming together Annu Rev Genomics Hum Genet 15 2014 151 171